Modelamiento y control digital de temperatura para horno eléctrico

Ingeniero (a) ElectrónicoPregrad

Game & Play: La cultura del juego digital

Peer-reviewedGame & Play: La cultura del juego digital ha reunido una serie de ponencias sobre los aspectos sociales y culturales del universo de los juegos digitales. A partir de distintas aproximaciones teóricas y metodológicas, los ponentes han analizado las características de los juegos,los creadores y los jugadores. Asimismo, han reflexionado sobre diferentes cuestiones relacionadas con la imagen de los juegos en los medios de comunicación o los valores que trasmite el juego digital. En general, los ponentes han centrando su atención en los juegos digitales como objetos mediados por las experiencias de sus creadores y sus usuarios y por los medios y otras instituciones. Los investigadores reunidos en el simposio provienen de campos como la comunicación, la educación, la teoría y la estética del arte y los estudios narrativos y literarios.Game & Play: La cultura del joc digital ha reunit una sèrie de ponències sobre els aspectes socials i culturals de l'univers dels jocs digitals. A partir de diferents aproximacions teòriques i metodològiques, els ponents han analitzat les característiques dels jocs,els creadors i els jugadors. Així mateix, han reflexionat sobre diferents qüestions relacionades amb la imatge dels jocs en els mitjans de comunicació o els valors que transmet el joc digital. En general, els ponents han centrant la seva atenció en els jocs digitals com a objectes intervinguts per les experiències dels seus creadors i els seus usuaris i pels mitjans i altres institucions. Els investigadors reunits en el simposi provenen de camps com la comunicació, l'educació, la teoria i l'estètica de l'art i els estudis narratius i literaris.Game & Play: The digital game culture has gathered a series of presentations on the social and cultural aspects of the digital game universe. Based on different theoretical and methodological approaches, the speakers analyzed the characteristics of the games, the creators and the players. They have also reflected on different issues related to the image of games in the media or the values transmitted by the digital game. In general, the speakers have focused their attention on digital games as objects mediated by the experiences of their creators and their users and by the media and other institutions. The researchers gathered at the symposium come from fields such as communication, education, the theory and aesthetics of art and narrative and literary studies

Correction to: Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry

International audienceIn this article, the name of the GLORIA-AF investigator Anastasios Kollias was given incorrectly as Athanasios Kollias in the Acknowledgements. The original article has been corrected

Patterns of oral anticoagulant use and outcomes in Asian patients with atrial fibrillation: a post-hoc analysis from the GLORIA-AF Registry

Background: Previous studies suggested potential ethnic differences in the management and outcomes of atrial fibrillation (AF). We aim to analyse oral anticoagulant (OAC) prescription, discontinuation, and risk of adverse outcomes in Asian patients with AF, using data from a global prospective cohort study. Methods: From the GLORIA-AF Registry Phase II-III (November 2011-December 2014 for Phase II, and January 2014-December 2016 for Phase III), we analysed patients according to their self-reported ethnicity (Asian vs. non-Asian), as well as according to Asian subgroups (Chinese, Japanese, Korean and other Asian). Logistic regression was used to analyse OAC prescription, while the risk of OAC discontinuation and adverse outcomes were analysed through Cox-regression model. Our primary outcome was the composite of all-cause death and major adverse cardiovascular events (MACE). The original studies were registered with ClinicalTrials.gov, NCT01468701, NCT01671007, and NCT01937377. Findings: 34,421 patients were included (70.0 ± 10.5 years, 45.1% females, 6900 (20.0%) Asian: 3829 (55.5%) Chinese, 814 (11.8%) Japanese, 1964 (28.5%) Korean and 293 (4.2%) other Asian). Most of the Asian patients were recruited in Asia (n = 6701, 97.1%), while non-Asian patients were mainly recruited in Europe (n = 15,449, 56.1%) and North America (n = 8378, 30.4%). Compared to non-Asian individuals, prescription of OAC and non-vitamin K antagonist oral anticoagulant (NOAC) was lower in Asian patients (Odds Ratio [OR] and 95% Confidence Intervals (CI): 0.23 [0.22-0.25] and 0.66 [0.61-0.71], respectively), but higher in the Japanese subgroup. Asian ethnicity was also associated with higher risk of OAC discontinuation (Hazard Ratio [HR] and [95% CI]: 1.79 [1.67-1.92]), and lower risk of the primary composite outcome (HR [95% CI]: 0.86 [0.76-0.96]). Among the exploratory secondary outcomes, Asian ethnicity was associated with higher risks of thromboembolism and intracranial haemorrhage, and lower risk of major bleeding. Interpretation: Our results showed that Asian patients with AF showed suboptimal thromboembolic risk management and a specific risk profile of adverse outcomes; these differences may also reflect differences in country-specific factors. Ensuring integrated and appropriate treatment of these patients is crucial to improve their prognosis. Funding: The GLORIA-AF Registry was funded by Boehringer Ingelheim GmbH

Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo

BACKGROUND: Cardiovascular (CV) disease is the leading cause of morbidity and mortality in patients with type 2 diabetes mellitus (T2DM). Furthermore, patients with T2DM and acute coronary syndrome (ACS) have a particularly high risk of CV events. The glucagon-like peptide 1 receptor agonist, lixisenatide, improves glycemia, but its effects on CV events have not been thoroughly evaluated. METHODS: ELIXA (www.clinicaltrials.gov no. NCT01147250) is a randomized, double-blind, placebo-controlled, parallel-group, multicenter study of lixisenatide in patients with T2DM and a recent ACS event. The primary aim is to evaluate the effects of lixisenatide on CV morbidity and mortality in a population at high CV risk. The primary efficacy end point is a composite of time to CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for unstable angina. Data are systematically collected for safety outcomes, including hypoglycemia, pancreatitis, and malignancy. RESULTS: Enrollment began in July 2010 and ended in August 2013; 6,068 patients from 49 countries were randomized. Of these, 69% are men and 75% are white; at baseline, the mean ± SD age was 60.3 ± 9.7 years, body mass index was 30.2 ± 5.7 kg/m(2), and duration of T2DM was 9.3 ± 8.2 years. The qualifying ACS was a myocardial infarction in 83% and unstable angina in 17%. The study will continue until the positive adjudication of the protocol-specified number of primary CV events. CONCLUSION: ELIXA will be the first trial to report the safety and efficacy of a glucagon-like peptide 1 receptor agonist in people with T2DM and high CV event risk